Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

481

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

27 drugs in development

Phase 31

Phase 216

Phase 110

Preclinical3

By Therapeutic Area

top 2

Oncology

2071%

Infectious Disease

27%

R&D Momentum

81/100

Pipeline Velocity

43/100

Trial Completion Rate

66/100

Pipeline Concentration

56/100

Pipeline Freshness

51/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Active, not recruiting

A Safety Study of Intraoperative Radiation Therapy Following Stereotactic Body Radiation Therapy and Multi-agent Chemotherapy in the Treatment of Localized Pancreatic Adenocarcinoma

Sep 18, 2026

Terminated

A Pilot Study of Stereotactic Radiosurgical Hypophysectomy for Intractable Pain From Bone Metastases

Sep 11, 2026

Active, not recruiting

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.

Sep 9, 2026

Active, not recruiting

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors

Earlier

Sep 5, 2026TrialTotal Pancreatectomy With Islet Autotransplantation (TPIAT) for Patients With Periampullary Neoplasms at High Risk for Pancreaticojejunostomy Leakage After Pancreaticoduodenectomy: a Single-center, Prospective, Single-Arm, Observational Study

Sep 4, 2026TrialA Cardiometabolic Screening Program for Breast Cancer Survivors

Sep 4, 2026TrialA Pilot Study of Low Versus High Intensity Patient Navigation Program to Improve the Enrollment on Clinical Trials Among Cancer Patients

Sep 4, 2026TrialA Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics

4 more events

Sep 2, 2026TrialPhase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Sep 2, 2026TrialExploring the Use of Tumor Informed Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)

Aug 29, 2026TrialA Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Aug 27, 2026TrialSafety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Oncology(20 drugs)

—

Oncology(20 drugs)

Unknown / Other(6 drugs)

—

Unknown / Other(6 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)